Skip to main content
Evidence Snapshot

Tissue factor

CHEMBL4081 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4081
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tissue factor as ChEMBL target CHEMBL4081, mapped to UniProt P13726. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tissue factor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4081
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P13726
Tissue factor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tissue factor matters

As of 2026-09-14

Tissue factor is reviewed as Tissue factor (UniProt P13726); Tissue factor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 200 compounds, and 31 assays, with lead potency reaching pChEMBL 10.6.

Disease context
cancer

Tissue factor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include TISOTUMAB VEDOTIN.

Start review with cancer because it currently carries approved-linked support. Linked drugs include TISOTUMAB VEDOTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 0 approved drugs, 200 compounds, and 31 assays for this target. The dominant activity type is IC50. CHEMBL4066780 is the current potency anchor at pChEMBL 10.6.

Use CHEMBL4066780 as the tractability anchor when discussing potency (pChEMBL 10.6).

Activity source · ChEMBL 36 via Core Engine
pChEMBL 10.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tissue factor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P13726, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

200
Total Compounds
31
Total Assays
0
Approved Drugs
IC50: 122.0, KI: 49.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4066780
 10.6 IC50 —
No preferred name
CHEMBL510111
 10.5 IC50 —
No preferred name
CHEMBL17201
 10.3 IC50 —
No preferred name
CHEMBL230128
 10.3 IC50 —
No preferred name
CHEMBL4070749
 10.1 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4081